Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2016-11-18FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for Cardizem LA (diltiazem hydrochloride extended-release) submitted by Bausch Health US LLC.
-
FDA approval · 2016-11-18FDA Approved: DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for Diltiazem hydrochloride extended-release from Oceanside Pharmaceuticals. The product is a calciu…
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals Inc)
FDA approved a supplemental application for Verapamil hydrochloride from Teva Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension [Phase 3]
Phase 3 trial update comparing oral valsartan/amlodipine combination therapy to amlodipine monotherapy in stage II hypertension. The update …
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension [Phase 3]
Phase 3 trial evaluating the efficacy and safety of aliskiren and atenolol in adults with mild to moderate hypertension has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (EXELA PHARMA SCIENCES, LLC)
The FDA approved a supplemental application for verapamil hydrochloride from Exela Pharma Sciences, LLC.
-
FDA approval · 2016-11-18FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for diltiazem hydrochloride. The approval confirms a modification to the pr…
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg [Phase 3]
This update reports the completion of a Phase 3 study evaluating the 12-month safety of the combination of aliskiren and hydrochlorothiazide…
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension [Phase 3]
Phase 3 trial of SPP100 (Aliskiren) regimen in patients with severe hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension [Phase 3]
Phase 3 trial comparing an oral valsartan/amlodipine combination to amlodipine monotherapy in Black patients with stage II hypertension has …
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension [Phase 3]
A Phase 3 trial comparing SPP100 (aliskiren) 150 mg to placebo and to losartan 50 mg in adults with mild to moderate essential hypertension …
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients [Phase 2]
Phase 2 trial comparing aliskiren plus valsartan with ramipril plus telmisartan in hypertensive patients to assess effects on the RAAS; stud…
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age [Phase 3]
This clinical trial update reports on a Phase 3 study evaluating valsartan for treating hypertension in children aged 6 to 16, with follow-u…
-
FDA approval · 2016-11-18FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for Cardizem CD (diltiazem hydrochloride) submitted by Bausch Health US LLC.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients [Phase 3]
A completed Phase 3 clinical trial evaluating the fixed-dose combination of valsartan and amlodipine for hypertension.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy [Phase 3]
This is a Phase 3 trial evaluating the combination of valsartan and amlodipine for hypertension not adequately controlled on monotherapy. Th…
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome [Phase 4]
This notice reports the completion of a Phase 4 trial evaluating the effect on insulin sensitivity of valsartan 320 mg and hydrochlorothiazi…
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction [Phase 3]
This entry reports the completion of a Phase 3 clinical trial evaluating SPP100 (aliskiren) regimens in hypertensive patients with renal dys…
-
FDA approval · 2016-11-17FDA Approved: TELMISARTAN AND AMLODIPINE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original application for a generic fixed-dose combination tablet of telmisartan and amlodipin…
-
FDA approval · 2016-11-16FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals, Inc.'s supplemental application for Losartan Potassium, marking an approval of changes to the generic pr…
-
CLINICAL_TRIALS trial_result · 2016-11-16Clinical Trial Update: Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy [Phase 4]
A Phase 4 trial comparing a valsartan-based strategy with an amlodipine-based strategy in adults with Stage 1–2 hypertension or uncontrolled…
-
CLINICAL_TRIALS trial_result · 2016-11-15Clinical Trial Update: Early Identification and Action in CKD [NA]
A completed clinical trial investigating early identification and action strategies in chronic kidney disease and hypertension.
-
CLINICAL_TRIALS trial_result · 2016-11-09Clinical Trial Update: Pilot Study Testing Feasibility of Health Screening at Farm Site [NA]
A completed pilot study assessed the feasibility of conducting diabetes, hyperlipidemia, and hypertension health screening at a farm site.
-
CLINICAL_TRIALS withdrawal · 2016-11-09Clinical Trial Update: Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs
A University of Washington-sponsored clinical trial examining gene regions that may influence the effectiveness of antihypertensive drugs ha…
-
FDA approval · 2016-11-08FDA Approved: MATZIM LA — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for MATZIM LA, a diltiazem hydrochloride product from Actavis Pharma, Inc.